Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News Archive
Showing 1809 results
September 2019
-
Media Release
Entresto improved measures of heart structure and function in HFrEF patients in new Novartis study; additional data complement findings
Results from PROVE-HF trial show significant improvements in measures of cardiac structure and function at six months and one year in heart failure with reduced ejection fraction (HFrEF) patients[1… -
Media Release
Novartis PARAGON-HF trial suggests Entresto® benefit in HFpEF patients but narrowly misses primary endpoint
Entresto (sacubitril/valsartan) reduced the composite of total (first and recurrent) heart failure hospitalizations and cardiovascular death although narrowly missed statistical significance (p = 0.…
August 2019
-
Story Patient Perspectives
Living with HFpEF – a patient’s story
Cynthia lives with Heart Failure with preserved Ejection Fraction, a complex and challenging condition.
-
Key Release
Novartis ofatumumab demonstrates superiority versus Aubagio® in two head-to-head Phase III multiple sclerosis studies
In ASCLEPIOS I and II, ofatumumab (OMB157) met primary endpoints to reduce the annualized relapse rate over Aubagio®* (teriflunomide) in patients with relapsing forms of MS (RMS)[1] Key secondary… -
Featured News
Blood Cancer Awareness Month - Cutting Edge Innovation in Hematology
Novartis is committed to transforming the lives of people living with blood cancers and serious blood disorders.
-
Featured News
Impact Measurement and Valuation
Novartis joins seven global companies to found the Value Balancing Alliance
-
Media Release
Novartis to present new Entresto HFpEF and HFrEF data at ESC Congress 2019
PARAGON-HF trial will provide Entresto® (sacubitril/valsartan) Phase III full results in heart failure with preserved ejection fraction (HFpEF)[1] New PROVE-HF and EVALUATE-HF studies will… -
Story People and Culture
Flexibility at Novartis: Shamsah Kazani
Kazani describes how her flexible work arrangement helps her balance her personal and professional lives.
-
Media Release
AveXis Statement on Changes to Senior Leadership Team
AveXis announces Page Bouchard, DVM has been appointed Senior Vice President of Research and Chief Scientific Officer, effective August 5, 2019. Dr. Bouchard is a 27-year industry veteran with… -
Media Release
Sandoz will appeal District Court of New Jersey ruling in biosimilar Erelzi® (etanercept-szzs) US patent case
Sandoz to appeal court ruling to United States Court of Appeals for the Federal Circuit Ruling prevents launch of important, affordable treatment option for US patients affected by chronic… -
Story Discovery
Using Super-Resolution Microscopy To See Neurodegeneration
Novartis data scientists are using super-resolution microscopy to see neurodegeneration the moment it starts.
-
Media Release
Novartis stands behind Zolgensma® (onasemnogene abeparvovec-xioi) for the treatment of children less than 2 years of age with spinal muscular atrophy
Basel, August 6, 2019 – Today the FDA released a statement addressing data integrity issues with the Biologics License Application (BLA) for Zolgensma® (onasemnogene abeparvovec-xioi). First and…